| 2025-11-05 |
详情>>
股本变动：
变动后总股本11339.08万股
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.09美元,归母净利润-1.29亿美元,同比去年增长13.74%
|
| 2025-09-09 |
详情>>
内部人交易：
Kooij Louise Frederika共交易3笔
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益-0.48美元,归母净利润-5689.1万美元,同比去年增长57.15%
|
| 2025-05-08 |
股东大会：
将于2025-06-04召开股东大会
会议内容 ▼▲
- 1.Opening
2.Discussion of the Dutch statutory board report for the fiscal year ended December 31, 2024 (discussion item)
3.Adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2024 (voting item)
4.Discharge from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2024 (voting item)
5.Instruction to Deloitte Accountants B.V. as the Company’s external auditor of the Company’s Dutch statutory annual accounts and Dutch statutory board report for the fiscal year ending December 31, 2025 (voting item)
6.Ratification of the selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 by the audit committee of the Company’s board of directors (the “Board of Directors”) (voting item)
7.Discussion of the Company’s dividend and reservation policy (discussion item)
8.Appointment of Wouter Joustra, Mark McKenna and Adele Gulfo as non-executive directors of the Company (voting items)
9.Reappointment of Michael Davidson, M.D. as executive director and Dr. James Topper as non-executive director of the Company (voting items)
10.Extension of authorization for the Board of Directors to acquire ordinary shares and depository receipts for ordinary shares in the Company’s capital (voting item)
11.Non-binding, advisory vote to approve the 2024 compensation of named executive officers (voting item)
12.Non-binding, advisory vote regarding frequency of future shareholders’ advisory votes on the compensation of named executive officers (voting item)
13.Closing
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.34美元,归母净利润-3952.7万美元,同比去年增长57.85%
|
| 2025-02-26 |
详情>>
业绩披露：
2024年年报每股收益-2.56美元,归母净利润-2.42亿美元,同比去年增长-36.54%
|
| 2024-12-10 |
复牌提示：
2024-12-10 06:55:00 停牌，复牌日期 2024-12-10 07:30:00
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.61美元,归母净利润-1.49亿美元,同比去年增长-17.25%
|
| 2024-10-28 |
详情>>
业绩披露：
2021年年报每股收益-1.21美元,归母净利润-2859.9万美元,同比去年增长-397.46%
|
| 2024-10-28 |
详情>>
业绩披露：
2022年年报每股收益-1.97美元,归母净利润-7805.2万美元,同比去年增长-172.92%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-1.45美元,归母净利润-1.33亿美元,同比去年增长-76.79%
|
| 2024-05-09 |
股东大会：
将于2024-06-05召开股东大会
会议内容 ▼▲
- 1.Discussion of the Dutch statutory board report for the fiscal year ended December 31, 2023
2.Adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2023
3.Discharge from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2023
4.Instruction to Deloitte Accountants B.V. as the Company’s external auditor of the Company’s Dutch statutory annual accounts and Dutch statutory board report for the fiscal year ending December 31, 2024
5.Discussion of the Company’s dividend and reservation policy
6.Ratification of the selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 by the audit committee of the Company’s board of directors (the “Board of Directors”)
7.Appointment of William H. Lewis as non-executive director of the Company
8.Reappointment of Louis Lange, M.D., Ph.D. as non-executive director of the Company
9.Extension of authorization for the Board of Directors to acquire ordinary shares and depository receipts for ordinary shares in the Company’s capital
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-1.06美元,归母净利润-9376.7万美元,同比去年增长-123.16%
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益-2.15美元,归母净利润-1.77亿美元,同比去年增长-126.69%
|
| 2023-05-31 |
股东大会：
将于2023-06-20召开股东大会
会议内容 ▼▲
- 1.Opening.
2.Discussion of Dutch statutory board report for the fiscal year ended December 31, 2022 (discussion item).
3.Adoption of Dutch statutory annual accounts for the fiscal year ended December 31, 2022 (voting item).
4.Discharge from liability for the Company’s directors with respect to the performance of their duties during the fiscal year ended December 31, 2022 (voting item).
5.Instruction to Deloitte Accountants B.V. for the external audit of the Company’s statutory annual accounts for the fiscal year 2023 (voting item).
6.Discussion of the Company’s dividend and reservation policy (discussion item).
7.Appointment of John William Smither as non-executive director of the Company (voting item).
8.Appointment of Hilde Johanna van der Kamp as non-executive director of the Company (voting item).
9.Reappointment of Johannes Jacob Pieter Kastelein as non-executive director of the Company (voting item).
10.Reappointment of Hugo Alexander Slootweg as non-executive director of the Company (voting item).
11.Reappointment of Nicholas Sinclair Downing as non-executive director of the Company (voting item).
12.Extension of authorization for the Board to acquire shares and depository receipts for shares in the Company’s capital (voting item).
13.Closing.
|
| 2022-10-18 |
股东大会：
将于2022-11-15召开股东大会
会议内容 ▼▲
- 1.The shareholders of NewAmsterdam Pharma (“Participating Shareholders”) will contribute all outstanding shares in the capital of NewAmsterdam Pharma to Holdco in exchange for the issuance of ordinary shares in the share capital of Holdco (“Holdco Shares”) (the “Exchange”);
2.Immediately after giving effect to the Exchange, the legal form of Holdco will be converted from a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) to a public limited liability company (naamloze vennootschap) (the “Holdco Reorganization”), provided that NewAmsterdam Pharma and FLAC may agree to effect the Holdco Reorganization promptly following the PIPE Financing (as defined below);
3.After giving effect to the Exchange, Merger Sub will merge with and into FLAC, with FLAC surviving the Merger as a wholly owned subsidiary of Holdco (the “Surviving Company”);
4.In connection with the Merger, each issued and outstanding ordinary share of FLAC will be canceled and extinguished in exchange for a claim for a Holdco Share, and such claim will then be contributed into Holdco against the issuance of a corresponding Holdco Share;
5.Immediately following the Merger, each outstanding warrant to purchase a FLAC Class A Ordinary Share (defined below) will become a warrant to purchase one Holdco Share, on the same contractual terms (“Holdco Warrants”);
6.Each NewAmsterdam Pharma option that is outstanding and unexercised (“NewAmsterdam Pharma Options”) will remain outstanding, and to the extent unvested, such option will continue to vest in accordance with its applicable terms, and at the time of the Exchange, such NewAmsterdam Pharma Options will become options to purchase, and will when exercised be settled in Holdco Shares;
7.Promptly following the Merger, the Surviving Company will change its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the “Domestication”);
8.Following the Merger, upon the achievement of a certain clinical development milestone, Holdco will issue to the Participating Shareholders (including Amgen and MTPC (each defined below) for this purpose) and holders of NewAmsterdam Pharma Options who were directors, officers, employees or consultants of NewAmsterdam Pharma as of the date of the Business Combination Agreement (the “Participating Optionholders”) and who are at the time of achievement of such milestone still providing services to Holdco or its subsidiaries, 1,886,137 additional Holdco Shares (the “Earnout Shares”), which in the case of the Participating Optionholders will take the form of awards of restricted stock units under Holdco’s long-term incentive plan. The development milestone consists of the achievement and public announcement of Positive Phase 3 Data (as defined in the Business Combination Agreement) for each of NewAmsterdam Pharma’s BROADWAY clinical trial and BROOKLYN clinical trial at any time during the period beginning on the Closing Commencement Date and ending on the date that is five years after the Final Closing Date. As a result, no Earnout Shares will be issuable if the applicable milestone is not achieved within five years of the Merger.
|